A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Macarena Ines De La Fuente, Howard Colman, Mark Rosenthal, Brian Andrew Van Tine, Danijela Levaci, Tobias Walbert, Hui Kong Gan, Maria Vieito, Mohammed M. Milhem, Kate Lipford, Sanjeev Forsyth, Sylvie Mireille Guichard, Yelena Mikhailov, Alexander Sedkov, Blythe Thomson, Patrick Francis Kelly, Varun Monga
Institutions: University of Miami, Sylvester Comprehensive Cancer Center, University of Utah, Huntsman Cancer Institute, Peter MacCallum Cancer Centre, Washington University in St. Louis, Baylor University, Baylor Scott & White Medical Center - Temple, Austin Health, Vall d'Hebron Institute of Oncology, University of Iowa, University of Iowa Holden Comprehensive Cancer Center, Forma Therapeutics (United States)
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3030441055